© 2023 MJH Life Sciences™ and Cannabis Patient Care. All rights reserved.
Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.
In a recent press release (1), Medical Marijuana Inc., announced it took part in a preclinical study in collaboration with the Center for Research and Advanced Studies of Neurological Diseases at the XXI Century National Medical Center in Mexico demonstrating the ability of cannabidiol (CBD) to decrease extracellular glutamate levels that can lead to traumatic brain injuries.
“Through this controlled study, we were able to observe that the oral administration of cannabidiol during the seven days prior to an injury helped to avoid the over-release of glutamate that results from brain trauma, an effect associated with decreased mortality in neurons,” said the leader of the study Dr. Luisa Rocha (1). “In this study, it was also shown that the application of CBD helps sensorimotor improvement. In fact, pre-injury CBD treatment was sufficient to lessen the aftermath of traumatic brain injury.”
According to the press release (1), Medical Marijuana, Inc., is a cannabis company in the non-psychoactive cannabinoid space with a global portfolio of cannabinoid-based nutraceutical brands and a cannabinoid-based clinical research and botanical drug development sector. The preclinical study used Medical Marijuana Inc.’s real scientific hemp oil (RSHO) CBD product, which contained no tetrahydrocannabinol (THC).
Additionally, HempMeds, a subsidiary of Medical Marijuana Inc., recently participated in a study testing the effectiveness of hemp-based cannabidiol (CBD) in treating Parkinson’s Disease (1).
“The results of this study further proves the therapeutic value of plant-based CBD,” said Blake Schroeder, CEO of Medical Marijuana, Inc. (1). “While federally funded research institutions in the US have been slow to embrace cannabis-based research, Latin American institutions have been performing this type of research in conjunction with our company for years. We will continue to pursue research in Mexico as well as in Brazil, where we are pursuing pharmaceutical registration of our products.”